Year :

Legend Biotech Chairman Frank Zhang awarded 2018 Person of the Year from China Healthcare Summit

Piscataway, NJ (November 14, 2018): China Healthcare Summit 2018 hosted by BioCentury and BayHelix announced Dr. Frank Zhang, GenScript’s founder, as the winner of its Person of the Year Award. The goal of this award was to recognize an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem of drug and/or medical technology R&D, […]

Nov 14, 2018

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen.Piscataway, NJ (May 30, 2018) – Legend Biotech, a subsidiary of GenScript Biotech Corporation (HKEx: 1548), announced today that the U.S. Food and Drug Administration (FDA) has authorized its development partner, Janssen Biotech, Inc. (“Janssen”), to commence a Phase 1b/2 […]

May 30, 2018

Nanjing Legend formally received the permission of a clinical trial granted by the CFDA with respect to LCAR-B38M CAR-T for autologous infusion

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the […]

Mar 13, 2018

Legend Biotech Announces Closing of Global Strategic LCAR-B38M CAR-T Cell Immunotherapy Collaboration with Janssen

Legend to receive an upfront payment of $350 million, as well as additional development, production performance, regulatory and sales milestone payments Legend and Janssen to co-develop and co-promote CAR-T cell therapy for multiple myeloma Profits and costs to be shared 50/50 worldwide, exclusive Greater China where 70 percent to Legend and 30 percent to Janssen […]

Dec 22, 2017

Legend Biotech Corporation Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Somerset, NJ (March 9, 2020): — Legend Biotech Corporation today announced that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of American depositary shares, representing its ordinary shares. The number of American depositary shares to be offered […]

Aug 26, 2022

Thank you for your interest in learning more about Legend Biotech.
Send us your questions or concerns.

Media Relations & Communications


You are about to leave

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.